Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | CPA2 | P48052 | 1/20 | 0.44 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.44 |
| ▸ | VHL | P40337 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617972 | 0.92 | ITGB1 (0.45) | F2ITGB1ITGA4CPA1CPA2 | |
| SCHEMBL29617974 | 0.92 | ITGB1 (0.45) | F2ITGB1ITGA4CPA1CPA2 | |
| SCHEMBL25634796 | 0.91 | ITGB1 (0.49) | F2ITGB1ITGA4CPA1CPA2 | |
| SCHEMBL28890641 | 0.88 | F2 (0.42) | F2ITGB1ITGA4XIAPGRB2 | |
| SCHEMBL17997394 | 0.88 | F2 (0.42) | F2ITGB1ITGA4XIAPGRB2 | |
| SCHEMBL29573758 | 0.86 | GRB2 (0.56) | XIAPGRB2STAT3OPRM1ACE | |
| SCHEMBL17274603 | 0.84 | KMT2A (0.39) | F2ITGB1ITGA4GRB2STAT3 | |
| SCHEMBL29572637 | 0.84 | DPP4 (0.47) | XIAPGRB2STAT3KMT2AOPRM1 | |
| SCHEMBL30121019 | 0.84 | ACE (0.49) | F2ITGB1ITGA4CPA1CPA2 | |
| SCHEMBL30563305 | 0.83 | GRB2 (0.44) | F2GRB2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213154-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213154-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | F2 3818/4885ITGB1 640/4885ITGA4 1923/4885 |
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | CTNNB1, CTNNBL1, CTNNA1 | F2 3818/4885ITGB1 640/4885ITGA4 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.